Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D03IKZ
|
|||
| Former ID |
DIB000970
|
|||
| Drug Name |
HBP-347
|
|||
| Synonyms |
HBP-347 (oral, cancer/autoimmunity/ocular disease); Hypericin (oral, cancer/autoimmunity/ocular disease), Hy BioPharma; HBP-347 (oral, cancer/autoimmunity/ocular disease), Hy BioPharma; Hypericin (oral, cancer/autoimmunity/ocular disease), Weizmann Institute/New York University; HBP-347 (oral, cancer/autoimmunity/ocular disease), Weizmann Institute/New York University
Click to Show/Hide
|
|||
| Indication | Autoimmune diabetes [ICD-11: 5A10] | Discontinued in Phase 3 | [1] | |
| Company |
Weizmann Institute of Science
|
|||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Heat shock protein 90 (Hsp90). SciBX 4(18). | |||
| REF 2 | US patent application no. 2013,0023,420, Susceptibility to hsp90-inhibitors. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.